Rhoifolin (Rho: 1, 3, and 5 μg/L) improved the locomotion pattern and reduced anxiety in the novel tank diving test (NTT). (A) Representative locomotion tracking pattern of the control, scopolamine (Sco: 100 μM), rhoifolin (Rho: 1, 3, and 5 µg/L), and imipramine (IMP: 20 mg/L) treated groups. (B) Representation of the time spent in the top zone by zebrafish in the tank in different groups. (C) Representation of the time spent in top/bottom ratio in different groups. (D) Representation of the total distance traveled by zebrafish in the tank in different groups. (E) Representation of the distance top/bottom ratio in different groups. The values are means ± S.E.M. (n = 10). For Tukey’s post hoc analyses: (B) Control vs. Sco (100 μM): ### p < 0.0001, Sco (100 μM) vs. Rho (1 μg/L): ## p < 0.001, Sco (100 μM) vs. Rho (3 μg/L): ### p < 0.0001 and Sco (100 μM) vs. Rho (5 μg/L): ### p < 0.0001; (C) Control vs. Sco (100 μM): ### p < 0.0001, Sco (100 μM) vs. Rho (1 μg/L): # p < 0.01, Sco (100 μM) vs. Rho (3 μg/L): ## p < 0.001, and Sco (100 μM) vs. Rho (5 μg/L): ### p < 0.0001; (D) Control vs. Sco (100 μM): ### p < 0.0001, Sco (100 μM) vs. Rho (1 μg/L): ### p < 0.0001, Sco (100 μM) vs. Rho (3 μg/L): ### p < 0.0001, and Sco (100 μM) vs. Rho (5 μg/L): ### p < 0.0001; (E) Control vs. Sco (100 μM): ### p < 0.0001, Sco (100 μM) vs. Rho (1 μg/L): # p < 0.01, Sco (100 μM) vs. Rho (3 μg/L): ### p < 0.0001, and Sco (100 μM) vs. Rho (5 μg/L): ### p < 0.0001.
|
